$ARGX

ARGENX SE

argenx is a biotechnology company that develops antibody-based medicines for autoimmune and neuromuscular diseases. Its commercial products include VYVGART and VYVGART HYTRULO, formulations of efgartigimod approved in indications including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; VYVDURA is the brand name used for efgartigimod in Japan for certain indications. argenx sells VYVGART through its own commercial teams in the U.S., Japan, Europe and Canada, and works with partners in some territories. Its agreement with Zai Lab covers development and commercialization of efgartigimod in Greater China, with argenx eligible for sales-based milestone payments and royalties. argenx also develops candidates including empasiprubart, a complement C2 inhibitor, and adimanebart, a MuSK agonist antibody. Its Immunology Innovation Program combines collaboration with academic researchers and in-house antibody engineering to generate medicines and product candidates. argenx is headquartered in Amsterdam, the Netherlands.

3
3
0

No SEC Form 4 filings for $ARGX in the last 30 days.

See all $ARGX insider activity →
Low

argenx Expands Cradle AI Platform for Antibody Discovery

argenx is expanding the use of Cradle's AI-driven protein engineering platform for antibody discovery. The company reports successful optimization of existing leads and generation of new antibody candidates. argenx aims to apply the platform to more programs, supporting its broader effort to develop antibody-based medicines.

ARGX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning ARGX (ARGENX SE). Coverage has skewed bullish: 3 bullish, 3 neutral, and 0 bearish.

Recent ARGX coverage spans financial news, technology and earnings.

What's driving ARGX

AlphAI scores every news story that mentions ARGX with an AI model for sentiment and relevance, and aggregates insider trades from ARGENX SE's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ARGX

Score

argenx Expands Cradle AI Platform for Antibody Discovery

argenx is expanding the use of Cradle's AI-driven protein engineering platform for antibody discovery. The company reports successful optimization of existing leads and generation of new antibody candidates. argenx aims to apply the platform to more programs, supporting its broader effort to develop antibody-based medicines.

Argenx Earnings Call Highlights Growth and 2027 Launches

Argenx reported Q3 revenue of $1.7B, up 54% YoY, driven by VYVGART sales growth. The company expects up to five U.S. launches in 2027, including potential approvals for pediatric and ocular MG, IMNM, and empasiprubart in MMN. Operating profit was $486M, with a 28% margin. Management highlighted strong financial position and pipeline progress, despite setbacks in dermatomyositis and Sjögren’s.

$ARGXHighAI 9/10

argenx (ARGX) to Acquire UNP for Up to Approximately $1.15B

argenx (ARGX) agreed to acquire Unnatural Products, Inc. (UNP) for up to $1.15B, including $550M in cash and $595M in milestones. The deal, expected to close by year-end, expands argenx's immunology research capabilities. According to argenx, UNP's peptide discovery platform complements its existing antibody engineering work.

$ARGXHighAI 9/10

argenx reports positive phase 3 data for autoimmune myositis drug

argenx SE (ARGX) reported positive Phase 3 results for VYVGART Hytrulo in treating autoimmune myositis, meeting primary and key secondary endpoints. The drug showed significant improvement in patients with immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) compared to placebo. The company plans to submit an FDA application by the end of 2026.

Related tickers